Fueling Life
Diffusion Pharmaceuticals LLC is a clinical-stage drug-development company commercializing first-in-class drug candidates. Our lead product candidate, trans sodium crocetinate (TSC), is a synthetic small-molecule that uses a novel method of action to enhance oxygen diffusion to oxygen-deprived (hypoxic) tissue. We believe that TSC has the potential to treat millions of patients annually for conditions in which hypoxia is present, including cardiovascular and respiratory diseases, stroke, cancer and other serious conditions with unmet medical needs.
A Phase I study of TSC in healthy subjects was successfully completed in 2007. In September 2008, the company initiated a Phase I/II proof-of-concept and dose-finding study in peripheral arterial disease patients suffering from intermittent claudication. Study completion and data unblinding are scheduled for early 2010. The annual market for a new peripheral arterial disease treatment is estimated at over a billion dollars in the United States alone.
Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia.
January 29, 2010
Diffusion Pharmaceuticals LLC Closes on $5.9 Million Financing
CHARLOTTESVILLE, VA – January 29, 2010 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced that it closed on $5.9 million in additional private financing during the second half of 2009, bringing the total the company raised in 2009 to $7.1 million. The [...]
January 4, 2010
Diffusion Pharmaceuticals LLC Announces Addition of Dr. David R. Jones as Chief Medical Officer, and Dr. Guy M. Chisolm Joins its Scientific Advisory Board
CHARLOTTESVILLE, VA – Wednesday, January 6, 2010 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced that David R. Jones, M.D., has joined its staff as Chief Medical Officer and member of its Scientific Advisory Board (SAB). In addition, Guy M. Chisolm, [...]
February 25, 2009
Diffusion Pharmaceuticals Featured in NPR Story on New Stroke Treatment
Scientists in Charlottesville are studying what could be a whole new approach to treating stroke—the nation’s leading cause of disability and the third leading cause of death. WVTF’s Sandy Hausman reports on the research.
Listen
Dr. Lee is chair of the Department of Neuroscience at the University of Virginia School of Medicine, and will present [...]
